Efficacy and safety of Russian tableted rizatriptan 10 mg in the treatment of migraine attacks in clinical practice
Open Access
- 20 August 2024
- journal article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 16 (4) , 41-48
Abstract
Triptans are a targeted therapy for acute migraine attacks. They are recommended for the treatment of severe attacks when non-specific analgesics are not effective. Four of the seven known triptans with different efficacy and individual tolerability are registered in the Russian Federation. Objective: to determine in an open-label non-comparative single center study efficacy and safety of the new Russian generic tableted rizatriptan 10 mg (Relonova) in real-life clinical practice. Material and methods. Thirty individuals with migraine took part in the study. Patients took rizatriptan to relieve 4 migraine attacks and filled out self-observation diaries and HIT-6 questionnaire before and after therapy. Results. The study involved 30 patients (26 women and 4 men) with mean age of 38.7 ± 9.3 years. Duration of migraine was 19.6 ± 11.4 years, mean number of days with migraine per month was 9.5 [5.25; 16.75]. Most patients (67 %) suffered from episodic migraine and 33 % from chronic migraine; 6 patients (20 %) had migraine attacks with aura; 20 individuals (67 %) received preventive therapy. After taking Relonova medication, pain relief was observed in 86 % of attacks, and in 45 % of cases pain disappeared completely; after 24 hours, pain relief was observed in 87 % of cases, and in 68 % – absence of attacks. A significant decrease in headache intensity was observed within 30 minutes after taking the first dose; in 34 % of attacks the headache returned. Additional analgesic treatment was required in 39 % of cases. Adverse events were observed in 25 % of attacks and were mild. The majority (63 %) of the participants were able to successfully terminate 3 attacks and were responders. Conclusion. Relonova is an effective and safe medication for the relief of migraine attacks.Keywords
This publication has 19 references indexed in Scilit:
- European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failureThe Journal of Headache and Pain, 2022
- Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk allelesNature Genetics, 2022
- Department of ErrorThe Lancet, 2017
- Genetics of Migraine: Insights into the Molecular Basis of Migraine DisordersHeadache: The Journal of Head and Face Pain, 2017
- The prevalence of primary headache disorders in Russia: A countrywide surveyCephalalgia, 2012
- Comparison of Rizatriptan 10 Mg vs. Zolmitriptan 2.5 Mg in the Acute Treatment of MigraineCephalalgia, 2000
- Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 1998
- Crossover Comparison of Rizatriptan 5 mg and 10 mg Versus Sumatriptan 25 mg and 50 mg in MigraineHeadache: The Journal of Head and Face Pain, 1998
- Rizatriptan (MAXALT) for the Acute Treatment of Migraine and Migraine Recurrence. A Placebo‐Controlled, Outpatient StudyHeadache: The Journal of Head and Face Pain, 1998
- Epidemiology of headache in a general population—A prevalence studyJournal of Clinical Epidemiology, 1991